New perspectives: role of Sunitinib in Breast Cancer
作者： F. Tomao , B. Vincenzi , M. E. Fratto , D. Santini , Giuseppe Tonini
DOI:
关键词:
摘要: Sunitinib malate (SU11248) is a multitarget oral tyrosine kinase receptor (RTKs) inhibitor which was approved by FDA in renal cells carcinoma (RCC) and imatinib-resistant or imatinib-intollerant gastro-intestinal stromal tumour (GIST). able to inhibit RTKs such as receptors for platelet-derived growth factor (PDGF-Rα β) vascular endothelial (VEGFRs). It KIT receptor, colony stimulating type 1 (CSF-1R), glial cell line neutrophic (RET), fms-like receptor-3 (FLT-3 CD135), signal transducer activator of transcription 3 (STAT3) AKT (protein B) cells. Many targets play important roles survival human breast cancer (BC). The "rationale" BC (with without others antiagiogenetic therapy) its ability block simultaneously intracellular portion inhibiting many downstream signals. We overviewed the most relevant studies concerning metastatic BC.
elsevier.com参考文章(28)
Marc D. Coltrera, Allen M. Gown, Peggy L. Porter, Jian Wang, Expression of Platelet-derived Growth Factor B-Chain and the Platelet-derived Growth Factor Receptor β Subunit in Human Breast Tissue and Breast Carcinoma Cancer Research. ,vol. 55, pp. 2703- 2708 ,(1995)
L. Seymour, D. Dajee, W. R. Bezwoda, Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer Breast Cancer Research and Treatment. ,vol. 26, pp. 247- 252 ,(1993) , 10.1007/BF00665802
Annelie Liljegren, Jonas Bergh, Roser Castany, Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer The Breast. ,vol. 18, pp. 259- 262 ,(2009) , 10.1016/J.BREAST.2009.07.005
A. Roussidis, A. Theocharis, G. Tzanakakis, N. Karamanos, The Importance of c-Kit and PDGF Receptors as Potential Targets for Molecular Therapy in Breast Cancer Current Medicinal Chemistry. ,vol. 14, pp. 735- 743 ,(2007) , 10.2174/092986707780090963
Lesley J. Murray, Tinya J. Abrams, Kelly R. Long, Theresa J. Ngai, Lisa M. Olson, Weiru Hong, Paul K. Keast, Jacqueline A. Brassard, Anne Marie O'Farrell, Julie M. Cherrington, Nancy K. Pryer, SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clinical & Experimental Metastasis. ,vol. 20, pp. 757- 766 ,(2003) , 10.1023/B:CLIN.0000006873.65590.68
Lydia Nakopoulou, Kalliopi Stefanaki, Effie Panayotopoulou, Ioanna Giannopoulou, Pauline Athanassiadou, Hariklia Gakiopoulou-Givalou, Androniki Louvrou, Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: Correlation with proliferation Human Pathology. ,vol. 33, pp. 863- 870 ,(2002) , 10.1053/HUPA.2002.126879
Johannes S. de Jong, Paul J. van Diest, Paul van der Valk, Jan P. A. Baak, Expression of growth factors, growth‐inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis The Journal of Pathology. ,vol. 184, pp. 53- 57 ,(1998) , 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7
Napoleone Ferrara, Hans-Peter Gerber, Jennifer LeCouter, None, The biology of VEGF and its receptors. Nature Medicine. ,vol. 9, pp. 669- 676 ,(2003) , 10.1038/NM0603-669
H. Wildiers, C. Fontaine, P. Vuylsteke, M. Martens, J. Canon, W. Wynendaele, C. Focan, J. Degreve, R. Paridaens, SUCON Trial (SUnitinib CONsolidation Therapy in Metastatic Breast Cancer): A Belgian Multicenter Phase II Randomized Trial in Her2 Negative Metastatic Breast Cancer Evaluating Consolidation Antiangiogenic Therapy with Sunitinib after Objective Response to Taxane Chemotherapy. Cancer Research. ,vol. 69, pp. 203- 203 ,(2009) , 10.1158/0008-5472.SABCS-09-203
Steven M. Jones, Richard Klinghoffer, Glenn D. Prestwich, Alex Toker, Andrius Kazlauskas, PDGF induces an early and a late wave of PI 3-kinase activity, and only the late wave is required for progression through G1. Current Biology. ,vol. 9, pp. 512- 521 ,(1999) , 10.1016/S0960-9822(99)80235-8